Skip Navigation
Return to All Schools

Erwin and Stephanie Greenberg Professorship of Urology

School of Medicine

Established in 2014 by Erwin Greenberg and Stephanie Cooper Greenberg

ERWIN L. GREENBERG is Founder and Chairman Emeritus of Greenberg Gibbons Commercial Corporation, developers of retail shopping centers in the Mid-Atlantic region and nationally based in Owings Mills, Maryland. STEPHANIE COOPER GREENBERG has had careers in banking, investment banking, small business ownership, fundraising and non-profit development in Boston, New Orleans, Washington and Baltimore.

Stephanie Cooper Greenberg is a member of the Board of Trustees at Johns Hopkins Bayview Medical Center as well as serves on several Advisory Boards including the Johns Hopkins Center for Innovative Medicine at Bayview, the Johns Hopkins Children’s Center, Rheumatology Advisory Board and Berman Institute of Bioethics. She is also a member of the board of the Kennedy Krieger Institute and the State of Maryland Cancer Control Board. Erwin and Stephanie Greenberg serve as directors of the Erwin & Stephanie Greenberg Foundation, which focuses its funding initiatives toward human service, education, and medical research.

Recognizing that, despite its prevalence, bladder cancer tends to receive less attention and funding than other cancers, Erwin and Stephanie chose to make a meaningful difference by directing their $15 million gift toward this single area of immense need. The Greenberg’s hope the co-investment with the Johns Hopkins University will help the Institute promote discovery, improve patient care and outcomes, and ultimately drive the global field of bladder cancer research closer to a cure.

Held by David J. McConkey

DAVID J. McCONKEY, PhD, inaugural director of the Johns Hopkins Greenberg Bladder Cancer Institute and Professor in the Department of Urology at Johns Hopkins Medicine, received his undergraduate degree from Brown University and completed his doctoral thesis work at the Karolinska Institute, Stockholm, Sweden. He performed his postdoctoral research at the Dana-Farber Cancer Institute before joining the faculty at University of Texas M.D. Anderson Cancer Center, where he served as Director of Urological Research from 2008-16. He is co-Principal Investigator of the M.D. Anderson Specialized Program of Research Excellence (SPORE) in Bladder Cancer, which is now in its third continuous cycle of funding from the National Cancer Institute (NCI). He is also Chair for Translational Medicine for the Genitourinary Cancers Committee in the Southwest Oncology Group (SWOG).

Research in Dr. McConkey’s laboratory is focused on using genomics to define the molecular mechanisms involved in bladder cancer progression and developing novel therapies. His mission is to make the Johns Hopkins Greenberg Bladder Cancer Institute a hub of an institutional and international community of researchers who share a commitment to advancing the scientific understanding of bladder cancer and improving its treatment.

Dr. McConkey has published more than 200 articles in peer reviewed journals and is on the editorial boards of Clinical Cancer Research and the Journal of Biological Chemistry. He served on 90 advisory committees at M.D. Anderson and won numerous teaching awards for his work. In 2016, Dr. McConkey was awarded the JPB Foundation Bladder Cancer Research Innovation Award from the Bladder Cancer Advocacy Network (BCAN) where he also serves as a member of their Scientific Advisory Board. Dr. McConkey is an active member of the American Urological Association (AUA), the Society for Urologic Oncology (SUO), and its research arm, the Society for Basic Urological Research (SBUR).